A Multi-centre Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Siponimod (Primary)
- Indications Polymyositis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 19 Feb 2017 Status changed from completed to discontinued.
- 26 Oct 2016 Status changed from discontinued to completed.
- 07 Oct 2016 Status changed from recruiting to discontinued.